Kintor Pharmaceutical KNTPF Stock
Kintor Pharmaceutical Price Chart
Kintor Pharmaceutical KNTPF Financial and Trading Overview
| Kintor Pharmaceutical stock price | 0.24 USD |
| Previous Close | 0.24 USD |
| Open | 0.57 USD |
| Bid | 0.21 USD x 250000 |
| Ask | 0.28 USD x 250000 |
| Day's Range | 0.57 - 0.57 USD |
| 52 Week Range | 0.17 - 0.57 USD |
| Volume | 100 USD |
| Avg. Volume | 3.78K USD |
| Market Cap | 119.68M USD |
| Beta (5Y Monthly) | -0.563 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.06 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
KNTPF Valuation Measures
| Enterprise Value | 220.8M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.5199577 |
| Price/Book (mrq) | 7.3058634 |
| Enterprise Value/Revenue | 2.804 |
| Enterprise Value/EBITDA | -1.641 |
Trading Information
Kintor Pharmaceutical Stock Price History
| Beta (5Y Monthly) | -0.563 |
| 52-Week Change | -7.26% |
| S&P500 52-Week Change | 15.74% |
| 52 Week High | 0.57 USD |
| 52 Week Low | 0.17 USD |
| 50-Day Moving Average | 0.22 USD |
| 200-Day Moving Average | 0.3 USD |
KNTPF Share Statistics
| Avg. Volume (3 month) | 3.78K USD |
| Avg. Daily Volume (10-Days) | 2.49K USD |
| Shares Outstanding | 498.66M |
| Float | 378.65M |
| Short Ratio | N/A |
| % Held by Insiders | 11.99% |
| % Held by Institutions | 9.92% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -244.63% |
| Operating Margin (ttm) | -155.47% |
| Gross Margin | 43.05% |
| EBITDA Margin | -170.84% |
Management Effectiveness
| Return on Assets (ttm) | -30.31% |
| Return on Equity (ttm) | -118.45% |
Income Statement
| Revenue (ttm) | 78.74M USD |
| Revenue Per Share (ttm) | 0.16 USD |
| Quarterly Revenue Growth (yoy) | 769.70% |
| Gross Profit (ttm) | 33.9M USD |
| EBITDA | -134516000 USD |
| Net Income Avi to Common (ttm) | -192620992 USD |
| Diluted EPS (ttm) | -0.06 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 31.3M USD |
| Total Cash Per Share (mrq) | 0.06 USD |
| Total Debt (mrq) | 133.58M USD |
| Total Debt/Equity (mrq) | 122.3 USD |
| Current Ratio (mrq) | 0.264 |
| Book Value Per Share (mrq) | 0.032850325 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -150910000 USD |
| Levered Free Cash Flow (ttm) | -81892376 USD |
Profile of Kintor Pharmaceutical
| Country | United States |
| State | N/A |
| City | Suzhou |
| Address | Suzhou Industrial Park |
| ZIP | 215123 |
| Phone | 86 51 2626 39909 |
| Website | https://www.kintor.com.cn |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 122 |
Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris that is in phase II clinical trial. The company is also developing ALK-1 Antibody (GT90001), an anti-angiogenesis inhibitor and targets a new biological target activin receptor-like kinase-1 globally to treat metastatic hepatocellular carcinoma, a common type of liver cancer, and a variety of solid tumours that is in phase I and II clinical trial; GT1708F (Hedgehog/SMO Inhibitor), an inhibitor of the hedgehog signal transduction pathway to treat idiopathic pulmonary fibrosis, and blood cancer that is in phase I clinical trial; and GT0486, an inhibitor of the PI3K/mTOR signalling pathway and a second generation mTOR inhibitor for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC) that is in phase I clinical trial. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.
Q&A For Kintor Pharmaceutical Stock
What is a current KNTPF stock price?
Kintor Pharmaceutical KNTPF stock price today per share is 0.24 USD.
How to purchase Kintor Pharmaceutical stock?
You can buy KNTPF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Kintor Pharmaceutical?
The stock symbol or ticker of Kintor Pharmaceutical is KNTPF.
Which industry does the Kintor Pharmaceutical company belong to?
The Kintor Pharmaceutical industry is Biotechnology.
How many shares does Kintor Pharmaceutical have in circulation?
The max supply of Kintor Pharmaceutical shares is 498.66M.
What is Kintor Pharmaceutical Price to Earnings Ratio (PE Ratio)?
Kintor Pharmaceutical PE Ratio is now.
What was Kintor Pharmaceutical earnings per share over the trailing 12 months (TTM)?
Kintor Pharmaceutical EPS is -0.06 USD over the trailing 12 months.
Which sector does the Kintor Pharmaceutical company belong to?
The Kintor Pharmaceutical sector is Healthcare.
